MONTEREY, CA, USA (UroToday) - This interesting study, the second of two presented by the Stanford University group, suggested that solifenacin reverses urodynamic and histologic detrusor changes associated with bladder outlet obstruction (BOO) in a mouse model. Treatment of patients with lower urinary tract symptoms (LUTS) often focuses on relief of BOO with alpha-blockers or 5-alpha reductase inhibitors, but recent attention has been paid to addressing secondary overactive bladder (OAB) symptoms.

In this study, a 6-week course of antimuscarinic therapy was instituted in 12/24 mice, six weeks after the onset of partial BOO. The animals were sacrificed twelve weeks after partial BOO occurred and following urodynamic studies. BOO was associated with urodynamics and histologic changes including decreased volume at first unstable contraction, increased bladder weight, and increased detrusor hypertrophy and fibrosis - the three former of which were reportedly reversed in mice following treatment with solifenacin.

Long-term studies in humans are necessary in order to establish the safety and efficacy of using solifenacin in human patients with BOO.

Presented by Craig Comiter, MD, at the 84th Annual Meeting of the AUA - Western Section - October 26 - 30, 2008 - Monterey, California

Reported by Alvaro Lucioni, MD, Virginia Mason Medical Center, Seattle, WA.

UroToday - the only urology website with original content global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday

Copyright © 2008 - UroToday

Tag Cloud